European Journal of Cardiovascular Medicine

Aims: To assess whether the expression of ER/PR/HER 2 status changes between the pre-operative biopsy specimen and post operated specimen in response to neoadjuvant chemotherapy in breast cancer patients. Materials and Methods: It is Comparative prospective study in 50 patients of breast cancer who visited to out patients department for treatment with neo adjuvant chemotherapy from one year were taken up.  Patients of age 18 -80years of age, ECOG less than I-III, Pathologically proven breast cancer (infiltrative ductal cell carcinoma) (IDCC) were included in study. A Structured form with the details like Age, tumour size, grade, nodal status, Stage and other details like oestrogen receptor, progesterone receptor status were noted. Results: Only 41 patients were available with residual tumour tissue in their post-operative histo-pathological reports which are assessed for ER/PR/HER 2 status. In this study total 36.6% patients were hormone receptor positive (either ER+VE or PR+VE), 63.4% patients were hormone receptor negative before neo adjuvant chemotherapy and after chemotherapy 31.7% patients were hormone receptor positive and 68.3% hormone receptor negative in which 17% patients have changed from HR+VE to HR-VE and 12% have changed from HR-VE to HR+VE with hormone receptor conversion rate of 29.26%. Before taking neo adjuvant chemotherapy 22% patients were progesterone receptor positive,78% patients were progesterone receptor negative and after chemotherapy 17.1% patients were progesterone receptor positive, 82.9% were progesterone receptor negative of which 9.76% patients change from PR+VE to PR-VE and 4.88% patients change from PR-VE to PR+VE with a concordance rate of 85.37% and discordance rate of 14.63%. Conclusions: There is high chances of change is receptor status before and after neoadjuvant chemotherapy so it advisable to check ER/PR/HER status in post neoadjuvant resected specimen. It is better to do re biopsy from the metastatic site and repeat IHC with ER/PR and HER-2 assay.